Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Gains from Investment Securities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Gains from Investment Securities for 9 consecutive years, with $1.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities rose 1629.38% to $1.6 million in Q2 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a N/A change, with the full-year FY2025 number at $1.7 million, up 3703.12% from a year prior.
  • Gains from Investment Securities was $1.6 million for Q2 2025 at Crescent Biopharma, down from $3.3 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.3 million in Q1 2025 to a low of -$90720.0 in Q4 2023.
  • A 5-year average of $995711.2 and a median of $251772.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 100.04% in 2021, then skyrocketed 88210.16% in 2025.
  • Crescent Biopharma's Gains from Investment Securities stood at -$2174.0 in 2021, then soared by 4353.22% to $92465.0 in 2022, then crashed by 198.11% to -$90720.0 in 2023, then surged by 203.66% to $94036.0 in 2024, then skyrocketed by 1629.38% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Gains from Investment Securities are $1.6 million (Q2 2025), $3.3 million (Q1 2025), and $94036.0 (Q2 2024).